AMOEBA (EPA:ALMIB) - AMOEBA SIGNS A MATERIAL TRANSFER AGREEMENT WITH BAYER FOR ITS BIOCONTROL SOLUTIONS

Transparency directive : regulatory news

22/04/2020 17:45

PRESS RELEASE

  AMOEBA SIGNS A MATERIAL TRANSFER AGREEMENT WITH BAYER FOR ITS BIOCONTROL
                               SOLUTIONS

Chassieu (France), april 22, 2020 - AMOEBA (FR0011051598 - AMEBA), producer of
a biological biocide capable of eliminating the risk in water and human wounds,
and of a biocontrol product for plant protection, still in the testing phase,
announces the signature of a Material Transfer Agreement (MTA) with BAYER, a
global enterprise with core competencies in the Life Science fields of health
care and agriculture. The purpose of this partnership is to evaluate the
performance of Amoéba's biocontrol solutions and, if tests are conclusive,
could lead to a possible business development partnership.

Bayer wishes to test, through its research partnership with Amoéba, biocontrol
solutions containing the amoeba lysate Willaertia magna C2c Maky.

These trials, conducted by the Crop Science division, in accordance with Bayer
internal procedures, will be carried out on various pathogens affecting crops.

" Because crops protection must be associated with the environment and
populations safeguard, Amoéba has demonstrated, through several partnerships
latest signings, the validity of its research to offer new natural
alternatives. The evaluation phases of our biocontrol products are scaling up
through these research agreements with major players in the sector, who could
become our customers if tests are conclusive." explains Fabrice Plasson,
Chairman and CEO of Amoéba

Amoéba points out that the company is still in the testing phase for its
biocide and biocontrol applications and does not currently market any products.

About AMOEBA:
Amoéba's ambition is to become a major player in the treatment of bacterial
risk in the fields of water, healthcare and plant protection. Our biological
solution is an alternative to chemical products widely used today. Amoéba is
currently focusing on the market of industrial cooling towers estimated at
EUR1.7Bn (1) on a global chemical biocide market for water treatment, evaluated
at EUR21Bn (2) and on the biocontrol market for plant protection estimated
globally at EUR1.6Bn (4). In the future, the Company is looking at developing
new applications such as chronic wound care, estimated at EUR 751 million (3)
in the USA. Sales of associated products with healthcare, biocides and crop
protection are subject to the Company being granted local regulatory market
authorizations. The Company is currently in a trial phase for biocidal and
plant protection applications and does not market any products.

Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada
and in the United States, Amoéba is quoted on the compartment C of Euronext
Paris. The Company is a member of the BPIfrance Excellence network and is
eligible for the PEA-PME SME equity savings plan setup. More information on
www.amoeba-biocide.com.
(1) : Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013
(2) : Sources combined by Amoéba from water treaters, Freedonia, Eurostat et
      MarketsandMarkets
(3): BCC Research, "Markets for Advanced Wound Management Technologies,"
     Wellesley, MA, 2017
(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

Contacts:
Amoéba
Valérie FILIATRE
General Manager
+33 (0)4 26 69 16 00
valerie.filiatre@amoeba-biocide.com

Investors and Media Relations
Grégory BOSSON / Mathieu CALLEUX
Agence Calyptus
+33(0)1 53 65 37 90
gregory.bosson@calyptus.net

Disclaimer
This press release contains certain forward-looking statements concerning
AMOEBA which are based on its own assumptions and hypothesis and on information
that are available to us. However, AMOEBA gives no assurance that the estimates
contained in such forward-looking statements will be verified, which estimates
are subject to numerous risks including the risks set forth in the reference
document of AMOEBA filed with the French Financial Markets Authority (Autorité
des Marchés Financiers) on April 25, 2019 under number D19-0383 and the
prospectus approved by the AMF on january 16, 2020 under number 20-011 (a copy
of which is available on www.amoeba-biocide.com). The forward-looking
statements contained in this press release are also subject to risks not yet
known to AMOEBA or not currently considered material by AMOEBA. The occurrence
of all or part of such risks could cause actual results, financial conditions,
performance or achievements of AMOEBA to be materially different from such
forward-looking statements.

AMOEBA's latest news

28/03/2024 18:30

AMOEBA (EPA:ALMIB) - AMOEBA SIGNS A MATERIAL TRANSFER AGREEMENT WITH BAYER FOR ITS BIOCONTROL SOLUTIONS

Transparency directive : regulatory news

AMOEBA's latest news

Other stories